1-4 of 4 results for subject:Pfizer
Librarians' tools
- Search time
- 0.184 seconds
- Solr query time
- 0.002 seconds
- Search query
- subject:Pfizer
- We searched for
- subject_t:Pfizer OR subject_ses:61578
Type
House
Session
Year
Department
Member
Primary member
Answering member
More
Legislative stage
Legislation
Subject
Publisher
To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 21 June 2022 to Question 17162 on Coronavirus: Vaccination for children, for what reason the covid-19 vaccination for five- to 11-year-olds was included in the NHS.UK vaccination schedule information for the purposes of raising...
To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 21 June 2022 to Question 17162 on Coronavirus: Vaccination for children, for what reason the covid-19 vaccination for five- to 11-year-olds was included in the NHS.UK vaccination schedule information for the purposes of raising...
While the Joint Committee on Vaccination and Immunisation’s one-off advice for a non-urgent offer of the Pfizer vaccine in this age group was publicised on NHS.UK to raise awareness, it does not reflect a change in policy.
COVID-19 vaccination is not included in the UK Health Security Agency’s routine childhood immunisation schedule, which provides immunisation information for health professionals and immunisation practitioners.
To ask the Secretary of State for Health and Social Care, what recent discussions he has had with relevant stakeholders on the availability of the Pfizer pill for covid-19 on the NHS.
To ask the Secretary of State for Health and Social Care, what recent discussions he has had with relevant stakeholders on the availability of the Pfizer pill for covid-19 on the NHS.
An updated interim clinical commissioning policy on the use of neutralising monoclonal antibody treatments and antivirals for non-hospitalised patients with COVID-19 was agreed by the United Kingdom Chief Medical Officers on 27 January 2022. This set out the intention to add PF-07321332+ritonavir (co-packaged as Paxlovid), manufactured by Pfizer, and remdesivir to the currently available treatment options for highest risk patients with COVID-19 from 10 February 2022.
NHS England has held webinars with stakeholders such as patient organisations, Royal Colleges, professional bodies and clinicians to support the introduction of the interim commissioning policy, with further engagement events and communications planned. Any decisions on deployment of community treatments, including Paxlovid, beyond the highest risk groups will be subject to the outcomes of the PANORAMIC study.
To ask the Secretary of State for Business, Energy and Industrial Strategy, whether the Government's contract for covid-19 vaccines with Pfizer includes an Investor State Dispute Settlement clause.
To ask the Secretary of State for Business, Energy and Industrial Strategy, whether the Government's contract for covid-19 vaccines with Pfizer includes an Investor State Dispute Settlement clause.
The Department of Business, Energy and Industrial Strategy has advised that it is unable to disclose the details of some clauses of contracts between the Government and vaccine manufacturers as this information is commercially sensitive.
To ask the Secretary of State for Health and Social Care, whether a person who receives the first dose of the Pfizer covid-19 vaccine in England and the second dose in the United States will be regarded as fully vaccinated for the purpose of entry requirements in the UK.
To ask the Secretary of State for Health and Social Care, whether a person who receives the first dose of the Pfizer covid-19 vaccine in England and the second dose in the United States will be regarded as fully vaccinated for the purpose of entry requirements in the UK.
The Health Protection (Coronavirus, International Travel and Operator Liability) (England) Regulations 2021 states a traveller who has received one vaccine in England and another in the United States of America will not be regarded as fully vaccinated for the purpose of entry into the United Kingdom having passed through or transited through an amber country in the last 10 days.